- Home
- CRL
as 07-25-2025 4:00pm EST
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
| Founded: | 1947 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 7.1B | IPO Year: | 2000 |
| Target Price: | $184.85 | AVG Volume (30 days): | 807.2K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $91.86 - $254.15 | Next Earning Date: | 08-06-2025 |
| Revenue: | $4,022,597,000 | Revenue Growth: | -2.17% |
| Revenue Growth (this year): | -2.79% | Revenue Growth (next year): | 2.49% |
Stock Insider Trading Activity of Charles River Laboratories International Inc. (CRL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MASSARO GEORGE | CRL | Director | May 15 '25 | Sell | $137.68 | 140 | $19,260.48 | 5,575 | |
| MASSARO GEORGE | CRL | Director | May 14 '25 | Sell | $142.38 | 140 | $19,702.90 | 5,575 | |
| LaPlume Joseph W | CRL | EVP, Corp Strategy & Develop | May 13 '25 | Sell | $145.41 | 500 | $72,705.00 | 19,513 |
Latest Charles River Laboratories International Inc. News
CRL Breaking Stock News: Dive into CRL Ticker-Specific Updates for Smart Investing
StockStory
a month ago
3 Reasons to Sell CRL and 1 Stock to Buy Instead
StockStory
a month ago
3 Unpopular Stocks in Hot Water
StockStory
a month ago
Drug Development Inputs & Services Stocks Q1 Recap: Benchmarking Fortrea (NASDAQ:FTRE)
StockStory
a month ago
Drug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV)
Business Wire
a month ago
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
Argus Research
a month ago
Analyst Report: Charles River Laboratories Int
Argus Research
a month ago
Market Update: BJ, CRL, PRGO, SPH
StockStory
a month ago
CRL Q1 Earnings Call: Regulatory Changes and Market Stabilization Shape Outlook
Compare CRL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRL Charles River Laboratories International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.